Curated News
By: NewsRamp Editorial Staff
October 12, 2026
Regentis Biomaterials to Present at 2026 ThinkEquity Conference
TLDR
- Regentis Biomaterials presents GelrinC at the 2026 ThinkEquity Conference, offering investors early access to a potential off-the-shelf cartilage repair solution.
- Regentis Biomaterials announced that CEO Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, in New York City.
- Regentis Biomaterials develops GelrinC, an off-the-shelf hydrogel that regenerates knee cartilage, potentially improving quality of life for patients with cartilage damage.
- Regentis Biomaterials will present its GelrinC technology and FDA Phase III trial progress at the 2026 ThinkEquity Conference on October 15, 2026.
Impact - Why it Matters
Regentis Biomaterials' participation in the ThinkEquity Conference comes at a pivotal time as the company advances its GelrinC technology through a Phase III trial and prepares for European commercialization. With no off-the-shelf treatment currently available for cartilage knee repair in the U.S., GelrinC could fill a significant gap in orthopedic care, potentially improving outcomes for hundreds of thousands of patients annually. The CE Mark approval in Europe validates the technology's safety and efficacy, positioning Regentis for near-term revenue generation. Investors should take note: successful trial results and market entry could drive substantial growth, making this a compelling story in the regenerative medicine space.
Summary
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company specializing in tissue repair solutions, has announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference. The event is scheduled for October 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will deliver an overview of the company's GelrinC® technology, recent clinical developments, and the progress of its ongoing U.S. Food and Drug Administration (FDA) pivotal Phase III trial. Additionally, he will discuss preparations for commercialization in Europe, where GelrinC has already received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings with investors, offering a valuable opportunity for direct engagement.
Regentis Biomaterials is dedicated to developing innovative solutions that restore health and enhance quality of life, with an initial focus on orthopedic treatments. The company's proprietary Gelrin platform technology utilizes synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage through a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. For more information, the full press release can be viewed at https://ibn.fm/wicmT. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT.
The announcement is disseminated through MissionIR (MIR), a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MIR is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. This engagement is part of a paid investor awareness and marketing campaign on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT).
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials to Present at 2026 ThinkEquity Conference
